Quintiles agrees drug development partnership with Huya
30 September 2010 00:00 in Marketing Services
Quintiles has entered into a co-development agreement with Huya Bioscience International in order to assist in bringing a new cancer drug to the global market.
The contract research organisation is to collaborate with Huya in conducting a phase I clinical study of HBI-8000, a treatment sourced from Chinese company Chipscreen Bioscience that has demonstrated anti-tumour efficacy and a good toxicity profile in early studies.
It is hoped this partnership can help to speed up the process of developing the treatment for a potential launch in Europe and the US.
Both companies said the agreement also illustrates the increasingly prominent benefits of western companies working with Chinese healthcare firms to carry out drug development.
Tom Perkins, senior vice-president of the capital group at Quintiles, said it "further illustrates our strategy to maximise the potential of global biopharmaceutical development and innovation for the benefit of patients".
Earlier this month, Quintiles was appointed by Pharmaxis to provide commercial solutions to support the European launch of the atrial fibrillation drug Bronchitol.
Other news stories from 30/09/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency